HCPCS M0233 is officially defined as "Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose." HCPCS M0233 is referenced in 12 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, BCBS Michigan, and 3 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS M0233 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of Rhode Island updated HCPCS Level II code coverage and payment rules effective April 1, 2026. Multiple codes have new coverage designations including newly covered codes, non-covered codes, medical review requirements, and pharmacy benefit changes.
Blue Cross Blue Shield of Michigan has implemented its Q1 2026 HCPCS code updates, adding 56 new codes and deleting 6 codes effective April 1, 2026. Most new skin substitute codes (A2040-A2045, Q4418-Q4440) are not covered, while new drug/injection codes (J-codes) and COVID-19 related codes are generally covered.
Texas Medicaid is implementing first quarter 2026 HCPCS updates effective April 1, 2026, adding new covered and non-covered procedure codes with specific age limitations and prior authorization requirements. Several existing codes are being discontinued with direct replacements required.
Texas Medicaid CSHCN Services Program is implementing Q1 2026 HCPCS updates effective April 1, 2026. Multiple codes are being added as benefits (pending rate hearings), added as non-covered, or discontinued entirely. Several new codes require prior authorization and have age restrictions.
Independence Blue Cross updated MA08.045o to MA08.045r effective 01/01/2026, expanding tocilizumab coverage criteria for COVID-19 to include pediatric patients aged 2 years and older, designating tocilizumab-aazg (Tyenne) as the preferred biosimilar product, and adding three new HCPCS codes (M0249, M0250, Q0249) retroactive to 06/24/2021. Billing teams must update systems to reflect the preferred product hierarchy and implement the new COVID-19 HCPCS codes.
Independence Blue Cross Medicare Advantage revised its tocilizumab policy (MA08.045r), effective and applied retroactively to September 21, 2026, to update criteria for cytokine release syndrome, immunotherapy toxicity and CAR T-cell neurotoxicity, add Kaposi sarcoma-associated inflammatory cytokine syndrome criteria, and revise the systemic juvenile idiopathic arthritis criteria. It also adds a long list of ICD-10 diagnosis codes as medically necessary, including groups M05, M06, C46, C90, C91, D47.Z2, D89.8 and G92.0.
Independence Blue Cross updated MA08.045q to MA08.045r (effective 07/01/2026), designating tocilizumab-anoh (Avtozma) as an additional preferred product alongside tocilizumab-aazg (Tyenne), and added three new HCPCS codes (M0231, M0232, Q0234) for tocilizumab-bavi COVID-19 treatment in hospitalized patients. Billing teams must update system configurations to recognize the new preferred product status and implement the new COVID-19 specific codes for claims processing.
Independence Blue Cross Medicare Advantage updated policy MA08.045p to MA08.045r, adding three new HCPCS codes (M0233, M0234, Q0238) for tocilizumab-aazg biosimilar COVID-19 treatment in hospitalized patients. The policy clarifies preferred versus nonpreferred tocilizumab products, establishes coverage criteria for multiple indications including rheumatoid arthritis and Castleman disease, and specifies that biosimilars require documented contraindication, intolerance, or inadequate response to preferred products before coverage of nonpreferred alternatives.
Independence Blue Cross updated policy 08.00.85s to version 08.00.85u, adding three new HCPCS codes (M0233, M0234, Q0238) for tocilizumab-aazg biosimilar infusions in hospitalized COVID-19 patients. The policy designates tocilizumab-aazg (Tyenne) and tocilizumab-anoh (Avtozma IV) as preferred products, with nonpreferred products requiring prior documentation of contraindication, intolerance, or inadequate response to preferred options.
The Indiana Health Coverage Programs (IHCP) set coverage and billing information for procedure codes added in the April 2026 quarterly HCPCS update, effective for dates of service on or after April 1, 2026. Codes marked noncovered are not covered for any IHCP program. Pricing for the new codes depends on CMS fee schedules that were still awaiting final posting, and claims submitted before pricing is entered into the claim-processing system may initially be denied.
The Indiana Health Coverage Programs (IHCP) set coverage and billing information for procedure codes in the April 2026 quarterly HCPCS update, effective for dates of service on or after April 1, 2026. This bulletin replaces the originally published update in IHCP Bulletin BT202649, and it sets prior authorization criteria for J3404, J9183, and the Q5161 and Q5162 biosimilars. Codes discontinued effective March 31, 2026 have no alternative codes identified by the IHCP, and codes marked allowed for podiatrists (provider specialty 140) are limited to that provider specialty.
Independence Blue Cross Medicare Advantage Policy MA08.045r (effective 07/01/2025) adds tocilizumab-anoh (Avtozma) as a newly preferred biosimilar product with HCPCS codes C9399 and J3590. The policy also expands Castleman disease coverage to allow tocilizumab as a substitute for siltuximab during shortage/unavailability and updates immunotherapy-related toxicity criteria per NCCN guidelines. All ICD-10 codes were removed as informational only.
Watch M0233
Get one email when a payer policy names M0233, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for M0233
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for M0233 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.